There could be a shortage of one to two billion syringes needed to administer Covid-19 vaccinations in 2022 which could also impact routine immunizations and undermine needle safety, the World Health Organization warned on November 9.

The world’s largest syringe maker does not have the capacity to substantially increase U.S. supplies of specialty syringes needed to squeeze more doses from Pfizer Inc. Covid-19 vaccine vials in the coming weeks, an executive said in an interview.

U.S. President-elect Joe Biden said he would order increased production of syringes and other supplies to ramp up vaccinations against Covid-19 and improve upon the Trump administration rollout that he called a “dismal failure.”

Pfizer’s partner BioNTech boosted the 2021 delivery target for their Covid-19 vaccine to 2 billion doses, up from 1.3 billion previously, as they bring new production lines on stream and as more doses can be extracted per vial.

During this webinar, learn more about benefits and risks of changing primary components during product development and how a design of experiments approach can be used to address issues and risks.

The U.S. FDA declined to approve a pre-filled syringe version of Regeneron Pharmaceuticals Inc.’s blockbuster eye drug Eylea.

The FDA approved 75 mg/0.5 mL and 150 mg/1 mL single-dose prefilled syringes for Genentech’s Xolair as an additional formulation for allergic asthma and chronic idiopathic urticaria.

A unit of AmerisourceBergen Corp. – one of the largest U.S. drug wholesalers – agreed to pay $625 million to resolve a U.S. government probe involving pre-filled syringes.